ArticleJournal of clinical microbiology2018
Diagnostic Accuracy and Utility of FluoroType MTBDR, a New Molecular Assay for Multidrug-Resistant Tuberculosis.
Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults.International journal of mycobacteriologyPooled it
- Pattern and prevalence of rifampicin and isoniazid-resistant tuberculosis using genotype MTBDRMicrobiology spectrum · 2026Article
- Diagnostic performance of the FluoroType MTBDR assay for rifampicin and isoniazid resistance in routine laboratory setting.African journal of primary health care & family medicine · 2026Article
- Uptake and rollout of the World Health Organization-endorsed technologies for Tuberculosis diagnosis in Africa: a literature review of international evidence 2007-2021.African health sciences · 2025Review
- Tuberculosis Today: Microbial Insights, Epidemiological Trends, and the Role of Molecular Diagnostics.Pathogens (Basel, Switzerland) · 2025Review
- Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Simultaneous detection and differentiation ofMicrobiology spectrum · 2025Article
- Evaluation of the cobas MTB and MTB-RIF/INH assay in clinical samples for the detection ofJournal of clinical microbiology · 2025Article
- Xpert MTB/RIF Ultra-resistant and MTBDRAntimicrobial agents and chemotherapy · 2025Article
- A duplex one-step recombinase aided PCR assay for the rapid and sensitive detection of the isoniazid resistance genes katG and inhA inFrontiers in microbiology · 2025Article
- The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa.Annals of the American Thoracic Society · 2024Article
- Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection ofResearch square · 2024Article
- New insight in molecular detection of Mycobacterium tuberculosis.AMB Express · 2024Review
- Isoniazid and Rifampicin Resistance-Conferring Mutations inPathogens (Basel, Switzerland) · 2023Review
- Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and Isoniazid.The Journal of molecular diagnostics : JMD · 2023Article
- Use of a FluoroTypeDiagnostics (Basel, Switzerland) · 2022Article
- Estimating tuberculosis drug resistance amplification rates in high-burden settings.BMC infectious diseases · 2022Article
- Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis.Infection and drug resistance · 2022Review
- Differential Diagnosis of Fungal Pneumonias vs. Tuberculosis in AIDS Patients by Using Two New Molecular Methods.Journal of fungi (Basel, Switzerland) · 2021Article
- Influence of anti-tuberculosis drugs plus cycloserine on sputum negative conversion rate, adverse reactions and inflammatory factors in multi-drug resistant tuberculosis.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Most cases of multidrug-resistant (MDR) tuberculosis (TB) are never diagnosed (328,300 of the ∼490,000 cases in 2016 were missed). The Xpert MTB/RIF assay detects resistance only to rifampin, despite ∼20% of rifampin-resistant cases being susceptible to isoniazid (a critical first-line drug). Consequently, many countries require further testing with the GenoType MTBDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.